A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2011
11/29/2011	US8067397 Transdiscal administration of cycline compounds
11/29/2011	US8067396 Amino alcohol compounds or phosphonic acid derivatives thereof
11/29/2011	US8067388 Decoy-containing pharmaceutical compositions and method of using the same
11/29/2011	US8067387 Method for stimulating angiogenesis using DKK2 and composition comprising the same
11/29/2011	US8067385 Antiviral oligonucleotides targeting HBV
11/29/2011	US8067381 Methods and compositions for increasing the anaerobic working capacity in tissues
11/29/2011	US8067380 Glutathione-based delivery system
11/29/2011	US8067379 Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
11/29/2011	US8067378 antiproliferative and less toxic removal of cancerous growths, metatastic tumors, reduction of glandular (e.g. prostate) hyperplasia; unwanted facial hair, warts, fatty tissue; preventing or inhibiting the stenosis, occlusion or blockage of a stent by coating the stent
11/29/2011	US8067377 Peptide compositions for targeting adipose tissue
11/29/2011	US8067376 Pharmaceutical compositions for transdermal delivery
11/29/2011	US8067375 Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
11/29/2011	US8067374 Adhesive hemostatic agent based on porcine atelocollagen and method for production thereof
11/29/2011	US8067373 Therapeutic fibrin-derived peptides and uses thereof
11/29/2011	US8067372 Modulation of angiogenesis by A-beta peptide fragments
11/29/2011	US8067371 Receptor for Advanced Glycation Endproducts (RAGE); rheumatoid arthritis; solubility
11/29/2011	US8067370 Microbiocide, pain relieving agent, antiseptic, analgesic, local anaesthetic, or kallikrein inhibitor in a matrix of a N-(2-hydroxypropyl)methacrylamide polymer crosslinked with kallikrein
11/29/2011	US8067369 Protection of the retina against laser injury by NAP and related peptides
11/29/2011	US8067368 Vascular endothelial growth factors and methods of their use
11/29/2011	US8067367 Methods of increasing platelet and hematopoietic stem cell production
11/29/2011	US8067366 Facilitation of resuscitation from cardiac arrest by erythropoietin
11/29/2011	US8067365 Erythropoietin for treatment of multi-organ failure
11/29/2011	US8067364 Deer antler extract for promoting angiogenesis
11/29/2011	US8067363 Compositions and methods for promoting lipid mobilization in humans
11/29/2011	US8067362 Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents
11/29/2011	US8067361 Chaperonin 10 immunosuppression
11/29/2011	US8067360 Method for promoting bone growth using activin-ActRIIa antagonists
11/29/2011	US8067359 Diabetic therapy; mixture of proteins, fats and carbohydrates
11/29/2011	US8067229 Ucp4
11/29/2011	US8067228 Nucleic acid compositions and their use against the hepatitic C virus
11/29/2011	US8067221 Von Willebrand factor (vWF)-cleaving protease
11/29/2011	US8067219 Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide
11/29/2011	US8067191 Method for detecting IL-16 activity and modulation of IL-16 activity based on rantes proxy protein levels
11/29/2011	US8067189 Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV
11/29/2011	US8067030 Controlled release composition and method of producing the same
11/29/2011	US8067028 Drug delivery device
11/29/2011	US8067025 Nitric oxide generating medical devices
11/29/2011	US8067023 Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
11/29/2011	US8067021 Methods and compositions for delivery of growth factor to fibrous connective tissue
11/29/2011	US8067020 Sustained release formulation
11/29/2011	US8067015 Delivery device for topical, oral, intravenous, intraperitoneal, intramuscular, transdermal, nasal, or iontophoretic administration coated with a RNAIII inhibiting heptapeptide of the sequence Tyr-X2-Pro-X1-Thr-Asn-Phe where X1 is Cys, Trp or Ile, and X2 is Lys or Ser; antibiotic resistance
11/29/2011	US8067010 Immunological herpes simplex virus antigens and methods for use thereof
11/29/2011	US8067008 Peptide inhibitors for mediating stress responses
11/29/2011	US8067007 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
11/29/2011	US8067006 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
11/29/2011	US8067004 Surface antigen
11/29/2011	US8067000 Cancer treatment with endothelin receptor antagonists
11/29/2011	US8066997 Modulation of activity of neurotrophins
11/29/2011	US8066991 Enzyme inhibitors of PAI-1
11/29/2011	US8066990 Lysin protein having broad antibacterial activity specific to bacteria
11/29/2011	US8066986 Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
11/29/2011	US8066981 Compositions and methods related to toll-like receptor-3
11/29/2011	US8066980 Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same
11/29/2011	US8066971 Targeting pulmonary epithelium using ADRP
11/29/2011	CA2638985C Therapeutic agent containing .omega.-feline interferon for treating feline atopic dermatitis
11/29/2011	CA2626531C Sodium chloride solution for drug reconstitution or dilution
11/29/2011	CA2513483C Injectable hydrogel microspheres from aqueous two-phase system
11/29/2011	CA2484166C Improved chimeric glycoproteins and pseudotyped lentiviral vectors
11/29/2011	CA2478645C Treatment of central nervous system damage
11/29/2011	CA2442909C Multimerization of hiv-1 vif protein as a therapeutic target
11/29/2011	CA2440461C Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
11/29/2011	CA2423227C Reduced-viscosity concentrated protein formulations
11/29/2011	CA2414331C Pd-l2 molecules: novel pd-1 ligands and uses therefor
11/29/2011	CA2409076C Composition and method for growing, protecting, and healing tissues and cells
11/29/2011	CA2401438C Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
11/29/2011	CA2297959C Use of erythropoietin and iron preparations for the production of pharmaceutical combination preparations for the treatment of rheumatic diseases
11/29/2011	CA2233447C Mimicking peptides in cancer therapy
11/27/2011	CA2752943A1 A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
11/24/2011	WO2011146845A1 Modified macrocyclic ghrelin receptor modulators and methods of using the same
11/24/2011	WO2011146574A1 Il-12 formulations for enhancing hematopoiesis
11/24/2011	WO2011146480A1 Biglycan mutants and related therapeutics and methods of use
11/24/2011	WO2011146408A1 Hpma polymer platinum chelates
11/24/2011	WO2011146121A1 Novel dna-binding proteins and uses thereof
11/24/2011	WO2011146109A2 Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
11/24/2011	WO2011146036A1 Medicinal multi-organ protection agent for treating conditions caused by cellular dysfunction
11/24/2011	WO2011145777A1 Pharmaceutical composition including an hif-2α inhibitor as an active ingredient for preventing or treating arthritis
11/24/2011	WO2011145723A1 Method for prevention or treatment of metabolic syndrome
11/24/2011	WO2011145553A1 Anti-inflammatory agent
11/24/2011	WO2011145307A1 Adiponectin production accelerating composition
11/24/2011	WO2011145125A1 Chimeric biomarker for the early diagnosis and immunotherapy of cancer
11/24/2011	WO2011145051A1 New uses of oxytocin-like molecules and related methods
11/24/2011	WO2011144924A1 Amine or amid analogues of sanglifehrin
11/24/2011	WO2011144916A1 Hemostatic compositions
11/24/2011	WO2011144818A1 Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions
11/24/2011	WO2011144756A1 Biosynthetic proline/alanine random coil polypeptides and their uses
11/24/2011	WO2011144751A1 Improved anti-serum albumin binding variants
11/24/2011	WO2011144714A1 Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt- jakob disease or diabetes mellitus
11/24/2011	WO2011144674A2 PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
11/24/2011	WO2011144673A2 Long - acting formulations of insulins
11/24/2011	WO2011144583A1 Combination therapy and method for assessing resistance to treatment
11/24/2011	WO2011144517A1 Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease
11/24/2011	WO2011143788A1 Novel glucagon like peptide analogs, composition, and method of use
11/24/2011	WO2011123858A3 Ccn3 peptides and analogs thereof for therapeutic use
11/24/2011	WO2011123830A3 Alpha 1-antitrypsin compositions and methods of making and using same
11/24/2011	WO2011115712A3 Tfpi inhibitors and methods of use
11/24/2011	WO2011112229A3 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
11/24/2011	WO2011110861A3 Therapy for influenza like illness
11/24/2011	WO2011109768A9 Compositions and methods for modulating cardiac conditions
11/24/2011	WO2011097581A9 THE USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
11/24/2011	WO2011094430A3 Pro-angiogenic fragments of prominin-1 and uses thereof

1 ... 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 ... 3163